











 1.　2019年 5月 10日（金）病理診断学分野担当
William F. Young, Jr. : Division of Endocrinology, Dia-
betes, Metabolism, Nutrition, and Internal Medicine, 
Mayo Clinic, Rochester, Minnesota, USA
“Challenging Adrenal Disorders and Clinical 
Scenarios : Illustrative Cases”
Abstract : Much progress has been made in the diagnosis 
and treatment of adrenal disorders over the past 4 decades.　
In this presentation I will highlight several examples where 
there have been key prismatic advances in the clinical under-
standing, laboratory testing, genetic testing, pathology, and 
treatment options for adrenal disorders.　Some of the topics 
to be discussed in this presentation include : the pathology-
based discovery of Cushing syndrome caused by primary pig-
mented nodular adrenocortical disease （PPNAD）; functioning 
adrenal neoplasms in pregnancy ; subtype evaluation of pri-
mary aldosteronism ; urine steroid metabolomics for the 
detection of adrenocortical carcinoma ; and, treatment options 
for patients with metastatic pheochromocytoma.　An illustra-





Professor Sir Stephen R. Bloom : Department of 
Medicine, Imperial College London
“Gut/brain peptide hormones regulating appetite 
and metabolism”
Abstract : In 1902 an activity was extracted from the gut 
mucosa in London which stimulated pancreatic secretion and 
was given the name secretin.　It was an exemplar of some-
thing released into the blood stream acting at a distance.　A 
Greek scholar of the day invented the word “hormone”.　
Sixty years later several further biological active peptides 
were identified in the gut.　These were subsequently shown 
to regulate appetite.　Many had a similar sequence to 
secretin.　They were the result of early gene duplication and 
subsequent evolution of more specialised functions.　These 
peptides have also identified in the brain and they clearly have 
separate, but related, functions in CNS control.　Their abnor-
mality in disease has been partly identified and they have also 
been modified to create new drugs, and used, for example to 
treat diabetes and obesity.
（文責 : 高橋和広）
 3.　2019年 5月 13日（月）難治性高血圧・内分泌代謝疾
患地域連携寄附講座
Prof. Martin Reincke : Medizinische Klinik und 
Poliklinik IV Klinikum der Universität München











 4.　2019年 7月 2日（火）病理診断学分野担当
Dr. David CL Lam, MD, PhD, FRCP, FCCP, FACP, 
FAPSR : Clinical Associate Professor, Department of 
Medicine, University of Hong Kong / Hong Kong SAR, 
China
“Targeting therapeutic biomarkers in lung cancer”
Abstract : Lung cancer is the leading cause of cancer death 
worldwide.　Non-small cell lung cancer （NSCLC）, with 
which lung adenocarcinoma, accounts for the majority of cases.　
Recent advances in the understanding of the molecular patho-
genesis of lung cancer together with the advancement of 
molecular analysis support the clinical use of targeted thera-
pies, such as epidermal growth factor receptor （EGFR） tyro-
sine kinase inhibitors （TKI） or anaplastic lymphoma kinase 
（ALK） TKI.　Further research into the drug resistance 
mechanisms and new opportunities to target those with or 
without acquired resistant mutations are much awaited.
Immunotherapy alone as a first treatment significantly 
improved survival for patients with a high level of the PD-L1 
protein in their cancer and with fewer side effects.　Immuno-
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therapy and chemotherapy combined therapy （IO-chemo） 
pushed the clinical benefits of immunotherapy further up in 
lung cancers.　Patients who had EGFR and ALK mutations 
used to show lesser therapeutic response to immunotherapy.　
There are recent research demonstrating an immunotherapy/
immunotherapy combination improved survival for those with 
a new biomarker of high tumor mutational burden （TMB）.　
Research into the the interaction between lung cancer cells 
and immune cells may reveal opportunities to better targeting 
immune reactions in lung cancer.
Precision medicine refers to the selection of treatment 
based on the presence of specific biomarkers which indicate 
sensitivity to corresponding therapies, may it be targeted 
therapies or therapy with lesser toxicity profile, so that patients 
will derive the most benefit from the selected treatments.　
Research into testing established and new therapeutic bio-
markers in the cancer helps inform treatment decisions.
While lung tumor tissue biopsy remains the gold standard 
for both histological diagnosis and molecular profiling, tissue 
biopsy is often limited by tumor accessibility because of the 
high risk and invasive nature of pulmonary intervention 
procedures.　Liquid biopsy aims at analysis of circulating bio-
markers in peripheral blood, such as circulating tumor cells 
（CTCs） and circulating tumor DNA （ctDNA）.　These act as 
alternative or supplementary source of cancer-derived infor-
mation that may be able to overcome the issue of representa-
tiveness of a small biopsy out of a sizable tumor.　Research 
into the heterogeneity of lung tumors may imply the presence 
of different malignant cell types in a suspicious lesion.　
Tumor-related biomarkers released into bloodstream could be 
assayed and that could reflect the molecular properties of can-
cer cells, their release or non-release may be helpful to sup-
port the clinical decision making.　There are indeed 
challenges that remain to be addressed before new circulating 
biomarkers could enter into routine clinical use.
（文責 : 笹野公伸）
 5.　2019年 7月 11日（木）消化器外科学分野担当
Associate Professor, Dan Duda : Harvard Medical 
School,　Massachusetts General Hospital, Steele Labo-
ratory for Tumor Biology
“Targeting stromal vulnerabilities to improve che-
motherapy and immunotherapy for liver cancers”
要旨 : 去る 7月 11日，東北医学会記念講演会が開催さ
れました．今回は，Harvard Medical School, Massachusetts 
General Hospital, Steele Laboratory for Tumor Biology の
Associate Professor, Dan Duda先生をお招きし，「Targeting 
stromal vulnerabilities to improve chemotherapy and immuno-







Tyrosine kinase inhibitor （TKI）である Sorafenib 以外に，
Regorafenibや Cabozantinibが FDAに認可され，さらに免
疫チェックポイント（Immunocheckpoint inhibitor : ICB）
の一つである Pembrolizumab （anti-PD1 antibody）の有用性
が示されている．ICBは近年注目されている治療であるが，
疾患によってはその効果は限定的であり，その主たる原因






























 6.　2019年 9月 25日（土）　心臓血管外科学分野担当
Payam Akhyari, MD, PhD. : Professor of Cardiovas-
cular Surgery, Heinrich Heine Universitat Duesseldorf 
“Clinical question-oriented cardiovascular research”
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要旨 : Issues in surgical therapy for cardiovascular disease 
is still paramount, our research activity can, therefore, encom-
pass substantial subjects on unsolved scientific myth.　Since 
our available time and resources dedicated to medical research 
are limited, it is crucial to focus on clinical question-oriented 
cardiovascular research.　In this lecture, some of those exam-
ples that our laboratory has engaged in will be shared with the 
colleagues in Tohoku University.
The number of surgical treatments for heart valves has 
steadily been increasing over the last decade.　Recently, the 
proportion of bioprosthetic valve use has been predominant 
compared to mechanical valve ; however, the longevity of 
those bioprosthetic valves is limited by long-term degenera-
tion and subsequent calcification, which leads to inevitable 
repeated surgeries imposing significant burden to our patients 
and society in terms of medical economy.　We have sought to 
develop a clinically practical means to solve this specific issue.　
Pioglitazone as a PPAR-gamma agonist is known to have 
not only an anti-diabetic effect but also anti-inflammatory and 
anti-arteriosclerotic action on the cardiovascular system.　
However, the effects of pioglitazone on cardiovascular biopros-
theses under diabetic conditions are unknown.　In this study, 
we aimed to examine the anti-inflammatory and anti-calcifica-
tion effects of pioglitazone on bioprosthetic aortic valve grafts 
in a small animal model of diabetes.　As a method for animal 
experiment, male Wister rats were fed with a high fat diet and 
randomly assigned to receive pioglitazone （group D+P ; n= 
8） or control （group D, n=8）.　Two weeks after diet induc-
tion intraperitoneal streptozotocin （STZ） injection （25 mg/
kg） was performed to complete the diabetic model.　Cryopre-
served aortic grafts including valves from donor rats were 
transplanted into the abdominal aorta.　After 4 weeks and 12 
weeks, 4 animals in each group underwent Doppler analysis 
and grafts were harvested.　Histopathologic analysis was per-
formed in 4 predefined sections of the grafts （A1, level of the 
aortic valve ; A2, ascending to proximal aortic arch ; B1, dis-
tal arch ; B2, descending aorta）.
We have obtained the results as following.　The combina-
tion of special diet plus STZ application led to significantly ele-
vated blood glucose levels in all animals.　Pioglitazone led to 
no significant reduction of glucose levels.　However, after 4 
weeks intima hyperplasia was significantly inhibited by piogli-
tazone （D ; 35.29±33.56 µm vs D+P ; 12.09±5.46 µm, p= 
0.028） and media thickness was significantly reduced （D ; 
141.85±25.37 µm vs D+P ; 100.27±28.82 µm ; p=0.003）.　
Calculation of calcification score based on von Kossa staining 
revealed significant reduction of intima calcification （D ; 2.75 
±3.09 points vs D+P ; 0±0 points, p=0.047） and media calci-
fication （D ; 7±3.27 points vs D+P ; 1.5±1.29 points, p= 
0.025） of mid-portion of the grafts （region A2） by pioglita-
zone.　This effect was also seen after 12 weeks （D ; 21.75± 
4.72 points vs D+P ; 10.75±5.97 points, p=0.048）.　As the 
interim conclusion, pioglitazone leads to inhibition of biopros-
thetic graft calcification, intima hyperplasia and media prolifer-
ation in a small animal model of diabetes.　Further experiments 
with long-term administration of pioglitazone and in-depth 
analysis of the underlying mechanisms are necessary.
（文責 : Payam Akhyari）
 7.　2019年 10月 16日（水）医化学分野担当
Professor Michael B. Sporn : Department of Pharma-
cology and Toxicology, Dartmouth Medical School, 
Hanover, New Hampshire, USA
“New Studies on Covalent Binding of CDDO-Imid-
azolides to Protein Targets, and Potential Clinical 
Applications”


































 8.　2019年 10月 21日（月）サイクロトロン核医学講座
Prof. Magdy M. KHALIL, Ph.D. : Dept. of Medical 
Physics, Faculty of Sciences, Helwan University, Egypt.
“Development of anatomically and lesion contrast-
guided partial volume correction : New 3D formal-
























 （文責 : 田代　学）
Prof. Kyeong Min KIM, Ph.D. : Division of RI-Con-
vergence Research, Korea Institute of Radiological and 
Medical Sciences （KIRAMS）, South Korea.
“Status of PET Application in evaluation of newly 
developed radiopharmaceuticals in Korea.”





という新規薬剤の治験が Korea Institute of Radiological and 
Medical Sciences （KIRAMS）との共同で実施され，最終的















 （文責 : 田代　学）
Prof. Hosna M.M. MOUSTAFA, M.D., Ph.D. : Nuclear 
Medicine Unit, Kasr Al-Ainy （NEMROCK Center）, 
Cairo University, Egypt.
“Trends and Essential topics in Nuclear Medicine in 
the Middle East.”

























 （文責 : 田代　学）
